培美曲塞单药治疗复治晚期肺腺癌27例疗效分析  

The Clinical Investigation of Efficacy by Pemetrexed for 27 Patients with Pulmonary Adenocarcinoma After Failure of First-Line Treatment

作　　者：肖鹏[1] 孟晶茜[2] 白桦[1] 栗敏[1] 孟祥瑞[1] 

机构地区：[1]郑州人民医院肿瘤内科,河南郑州450003 [2]郑州大学第二附属医院肾内科,河南郑州450014

出　　处：《肿瘤基础与临床》2011年第2期125-126,共2页journal of basic and clinical oncology

摘　　要：目的探讨培美曲塞单药治疗复治晚期肺腺癌的疗效及毒副反应。方法 27例复治晚期肺腺癌,给予培美曲塞500 mg/m2,静脉滴注,d1,每3周重复;并口服地塞米松、叶酸和肌内注射维生素B12以减轻毒副反应。每2个周期后进行疗效评价。结果 27例患者均可评价疗效,疗效评价为CR 0例,PR 3例,SD 10例,PD 14例,有效率11.1%（3/27）,疾病控制率48.1%（13/17）。中位无进展生存期2.8个月,中位生存期10.6个月。主要毒副反应为Ⅰ~Ⅱ度骨髓抑制和胃肠道反应。结论培美曲塞治疗复治晚期肺腺癌安全有效。Objective To evaluate the efficacy and toxicities by pemetrexed alone in the treatment of pulmonary adenocarcinoma after failure of first-line treatment.Methods The 27 patients were enrolled.All of these patients had been confirmed with pathology or cytology and received pemetrexed 500 mg/m2 on day 1,by intravenous infusion,with every 21 days.Dexamethasone,folic acid and vitamin B12 they were applied to relieve the drug toxicity.All the patients who received 2 or more cycles could be evaluated.Results There was no case with complete response.Three cases had partial response,10 cases stable disease and 14 cases had progressive disease.The response rate was 11.1%（3/27）.The disease control rate was 48.1%（13/27）.The median progression free survival was 2.8 months.The median overall survival was 10.6 months.The most common toxicities were grade Ⅰ-Ⅱ myelosuppression and gastrointestinal reaction.Conclusion Pemetrexed is effective and feasible for advanced recurrent pulmonary adenocarcinoma.

关 键 词：培美曲塞 复发 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]